AMRX:NYE-Amneal Pharmaceuticals, Inc. Class A Common Stock (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 8.9

Change

0.00 (0.00)%

Market Cap

USD 4.11B

Volume

1.93M

Analyst Target

USD 4.11
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-09 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 74.41B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 47.88B
HLN Haleon plc

N/A

USD 43.18B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 11.49B
ELAN Elanco Animal Health

N/A

USD 5.51B
BHC Bausch Health Companies Inc

N/A

USD 2.64B
CPHI China Pharma Holdings Inc

N/A

USD 3.69M
YCBD cbdMD Inc

N/A

USD 1.96M
APUS Apimeds Pharmaceuticals US, In..

N/A

N/A
EVT Eaton Vance Tax Advantaged Div..

N/A

N/A

ETFs Containing AMRX

MVR:AU VanEck Vectors Australian.. 6.38 % 0.00 %

N/A

USD 0.43B
AUCO:SW L&G Gold Mining UCITS ETF.. 5.61 % 0.00 %

N/A

N/A
ROYA 5.38 % 0.00 %

N/A

N/A
QRE:AU Beta Shares S&P/ASX 200Re.. 4.66 % 0.00 %

N/A

USD 0.21B
OZR:AU SPDR S&P/ASX 200 Resource.. 4.49 % 0.00 %

N/A

USD 0.17B
DAVA:AU Dimensional Australian Va.. 3.20 % 0.00 %

N/A

N/A
OAEM OneAscent Emerging Market.. 3.11 % 0.00 %

N/A

N/A
MVW:AU VanEck Vectors Australian.. 1.43 % 0.00 %

N/A

USD 2.68B
DLS WisdomTree International .. 0.00 % 0.58 %

N/A

N/A
FEM First Trust Emerging Mark.. 0.00 % 0.80 %

N/A

USD 0.40B
HAL:CA Global X Active Canadian .. 0.00 % 0.78 %

N/A

CAD 0.12B
RING iShares MSCI Global Gold .. 0.00 % 0.39 %

N/A

USD 1.07B
FEM:LSE First Trust Emerging Mark.. 0.00 % 0.00 %

N/A

USD 0.01B
FEMU:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 0.01B
IOGP:LSE iShares Oil & Gas Explora.. 0.00 % 0.00 %

N/A

N/A
SPOG:LSE iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A
ETLX:F L&G Gold Mining UCITS ETF 0.00 % 0.00 %

N/A

N/A
EXXW:F iShares Dow Jones Asia Pa.. 0.00 % 0.00 %

N/A

N/A
IQQX:F iShares Public Limited Co.. 0.00 % 0.00 %

N/A

N/A
IS0D:F iShares Oil & Gas Explora.. 0.00 % 0.00 %

N/A

N/A
ETLX:XETRA L&G Gold Mining UCITS ETF 0.00 % 0.00 %

N/A

USD 0.13B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.37% 86% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.37% 86% B+ 92% A
Trailing 12 Months  
Capital Gain 65.12% 93% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.12% 93% A 97% N/A
Trailing 5 Years  
Capital Gain 179.87% 100% F 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 179.87% 100% F 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 40.01% 93% A 91% A-
Dividend Return 40.01% 93% A 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 88.30% 29% F 10% F
Risk Adjusted Return 45.31% 79% B- 59% D-
Market Capitalization 4.11B 44% F 76% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.